Literature DB >> 18572327

Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder.

Ipek Işik Gönül1, Nalan Akyürek, Ayşe Dursun, Bora Küpeli.   

Abstract

Using the 1998 World Health Organization/International Society of Urological Pathology (WHO/ISUP) (2004 WHO), 1999 WHO/ISUP, and 1973 WHO classifications, we examined Ki67, BCL-2, TP53, and MDM-2 expressions in invasive and noninvasive urothelial neoplasias of the bladder of 72 patients, and compared the results regarding tumor category and grade with clinical outcome to determine the clinicopathological relevance of these classifications. Ki67 and TP53 expressions were correlated with tumor grades of the 1973 WHO classification, and they also distinguished "papillary urothelial neoplasm with low malignant potential" from other WHO/ISUP grades (p < 0.05). No difference was observed for Ki67 and TP53 expressions between the other WHO/ISUP grades (p > 0.05). Neither tumor grade nor tumor category correlated with MDM-2 or BCL-2 expressions (p > 0.05). WHO/ISUP classifications are obviously not superior to the 1973 WHO classification for grading urothelial neoplasia of the bladder. However, if the "papillary urothelial neoplasm with low malignant potential" is distinguished from grade 1 tumors of the 1973 WHO classification, more precise prognostic information may be obtained.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18572327     DOI: 10.1016/j.prp.2008.03.011

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  6 in total

1.  Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy.

Authors:  Lujia Wang; Minwei Zhou; Chenchen Feng; Peng Gao; Guanxiong Ding; Zhongwen Zhou; Haowen Jiang; Zhong Wu; Qiang Ding
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

2.  A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology.

Authors:  Floriane Michel; Fabiana Cancrini; Géraldine Cancel-Tassin; Xavier Gamé; Eric Huyghe; Aurélien Rock; Grégoire Léon; Audrey Uzan; François-Régis Desfemmes; Benoît Peyronnet; Jérémy Fallot; Priscilla Léon; Emmanuel Rolland; Marie-Aimée Perrouin-Verbe; Jacques Wodey; Grégoire Capon; Gilles Karsenty; Morgan Rouprêt; Olivier Cussenot; Hussa Alshehhi; Eva Comperat; Véronique Phé
Journal:  World J Urol       Date:  2022-02-09       Impact factor: 3.661

3.  Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.

Authors:  Abeer M Al-Ghananeem; Ahmad H Malkawi; Yahya M Muammer; Justin M Balko; Esther P Black; Walid Mourad; Edward Romond
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

4.  Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.

Authors:  Kien T Mai; Trevor A Flood; Phillip Williams; Zuzana Kos; Eric C Belanger
Journal:  Virchows Arch       Date:  2013-08-04       Impact factor: 4.064

Review 5.  High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.

Authors:  Yihuan Luo; Xin Zhang; Meile Mo; Zhong Tan; Lanshan Huang; Hong Zhou; Chunqin Wang; Fanglin Wei; Xiaohui Qiu; Rongquan He; Gang Chen
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

6.  Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivo murine model.

Authors:  Juan Riestra-Ayora; Carolina Sánchez-Rodríguez; Raquel Palao-Suay; Joaquín Yanes-Díaz; Ana Martín-Hita; María Rosa Aguilar; Ricardo Sanz-Fernández
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.